title: Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
abstract: We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277-488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226-21 532).
authors: Universidad Militar Nueva Granada, Santafé de Bogotá, Colombia, and Universidad del Bosque, Bogotá, Colombia.
authors: Juan Carlos
authors: JC
authors: Vega
authors: Boris Fernando
authors: BF
authors: Sanchez
authors: Luz Mery
authors: LM
authors: Montero
authors: Rafael
authors: R
authors: Montaña
authors: Mercedes
authors: M
authors: Del Pilar Mahecha
authors: Bladimir
authors: B
authors: Dueñes
authors: Angela Rocío
authors: AR
authors: Baron
authors: Richard
authors: R
authors: Reithinger
mesh_terms: D000981:Antiprotozoal Agents / Q000191:economics* / Q000627:therapeutic use; D003105:Colombia / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks / Q000191:economics*; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D008536:Meglumine / Q000191:economics* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000191:economics* / Q000627:therapeutic use
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate